Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ruoyang Jiao, Chu Lin, Shuzhen Bai, Xiaoling Cai, Suiyuan Hu, Fang Lv, Wenjia Yang, Xingyun Zhu & Linong Ji. (2023) The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy 24:4, pages 511-521.
Read now
Read now
Jun Inaishi & Yoshifumi Saisho. (2022) Exenatide Once Weekly for Management of Type 2 Diabetes: A Review. Clinical Pharmacology: Advances and Applications 14, pages 19-26.
Read now
Read now
Sebastian M. Heimbürger, Andreas Brønden, Nicklas J. Johansen, Thomas F. Dejgaard, Tina Vilsbøll & Filip K. Knop. (2019) The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 20:5, pages 501-510.
Read now
Read now
Chen Li, Shijie Dai, Aijie Cao, Zhifang Zhou & Zhimeng Wu. (2019) Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation. Journal of Carbohydrate Chemistry 38:3, pages 167-178.
Read now
Read now
Emanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, Fabrizio De Ponti & Giulio Marchesini. (2018) Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 19:17, pages 1903-1914.
Read now
Read now
Articles from other publishers (47)
Jian Ma, Liang Yan, Jingkui Yang, Yujian He & Li Wu. (2023) Effect of Modification Strategies on the Biological Activity of Peptides/Proteins. ChemBioChem.
Crossref
Crossref
Manjun Deng, Yonghao Wen, JingXin Yan, Yichen Fan, Zhixin Wang, Ruixia Zhang, Li Ren, Yinggui Ba, Haijiu Wang, Qian Lu & Haining Fan. (2023) Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMC Medicine 21:1.
Crossref
Crossref
Philipp Uhl, Gzona Bajraktari‐Sylejmani, Dominik Witzigmann, Cindy Bay, Stefan Zimmermann, Jürgen Burhenne, Johanna Weiss, Walter E. Haefeli & Max Sauter. (2023) A Nanocarrier Approach for Oral Peptide Delivery: Evaluation of Cell‐Penetrating‐Peptide‐Modified Liposomal Formulations in Dogs. Advanced Therapeutics 6:10.
Crossref
Crossref
Chaitra Chandrashekar, Yuji Nishiuchi, Barbara Fam White, Yanni Arsenakis, Feng Lin, Samantha M. McNeill, Peishen Zhao, Sam van Dun, Anna Koijen, Yasuhiro Kajihara, Denise Wootten, Leendert J. van den Bos, John D. Wade & Mohammed Akhter Hossain. (2023) Glycosylation Improves the Proteolytic Stability of Exenatide. Bioconjugate Chemistry 34:6, pages 1014-1018.
Crossref
Crossref
Kirsten M. Jansen, Norma Dahdah, Pau Gama-Perez, Pauke C. Schots, Terje S. Larsen & Pablo M. Garcia-Roves. (2023) Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration. Frontiers in Endocrinology 14.
Crossref
Crossref
Shuzhen Bai, Chu Lin, Ruoyang Jiao, Xiaoling Cai, Suiyuan Hu, Fang Lv, Wenjia Yang, Xingyun Zhu & Linong Ji. (2023) Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?. European Journal of Internal Medicine 109, pages 79-88.
Crossref
Crossref
Estel Collado Camps, Sanne A. M. van Lith, Annemarie Kip, Cathelijne Frielink, Lieke Joosten, Roland Brock & Martin Gotthardt. (2022) Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39). European Journal of Nuclear Medicine and Molecular Imaging 50:4, pages 996-1004.
Crossref
Crossref
Su Ann Tee, Vasileios Tsatlidis & Salman Razvi. (2023) The GLP‐1 receptor agonist Exenatide reduces serum TSH by its effect on body weight in people with Type 2 Diabetes. Clinical Endocrinology.
Crossref
Crossref
Joseph Nowell, Eleanor Blunt & Paul Edison. (2022) Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease. Molecular Psychiatry 28:1, pages 217-229.
Crossref
Crossref
Lei Wang, Nanxi Wang, Zhibin Yan, Zhifeng Huang & Caiyun Fu. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
795
815
.
Jun Inaishi, Yoshifumi Saisho, Yuusuke Watanabe, Tami Tsuchiya, Hironobu Sasaki, Tatsuhiro Masaoka & Hiroshi Itoh. (2022) Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study. BMC Endocrine Disorders 22:1.
Crossref
Crossref
Shiying Shao, Xiaoling Zhang, Qinqin Xu, Ruping Pan & Yong Chen. (2022) Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. Pharmacology & Therapeutics 239, pages 108270.
Crossref
Crossref
Xujing Liu, Aihua Zhai & Bai Zhang. (2022) A case report of severe adverse reaction of exenatide: Anaphylactic shock. Medicine 101:39, pages e30805.
Crossref
Crossref
Shu-Chang Wang, Xin-Nan Teng, Xu-Dong Wang, Yue-Sheng Dong, Heng-Li Yuan & Zhi-Long Xiu. (2022) Recycling reaction and separation for FACylation of loxenatide by trade-off between miscibility and immiscibility of reactants and product in methanol solution. Journal of Chromatography A 1676, pages 463239.
Crossref
Crossref
Joakim Ölmestig, Ida R. Marlet, Tina Vilsbøll, Jørgen Rungby, Egill Rostrup, Kate L. Lambertsen & Christina Kruuse. (2022) A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Manoj Kumar Mahapatra, Muthukumar Karuppasamy & Biswa Mohan Sahoo. (2022) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders 23:3, pages 521-539.
Crossref
Crossref
João C. Ribeiro, Ana D. Martins, Ivana Jarak, Rui A. Carvalho, Marco G. Alves & Pedro F. Oliveira. (2022) Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis. Biomedicines 10:5, pages 1115.
Crossref
Crossref
Ecem Bostan, Neslihan Akdogan & Ozay Gokoz. (2021) Paradoxical new‐onset psoriasiform dermatitis associated with exenatide administration. International Journal of Dermatology 61:3.
Crossref
Crossref
Lei Wang, Nanxi Wang, Wenping Zhang, Xurui Cheng, Zhibin Yan, Gang Shao, Xi Wang, Rui Wang & Caiyun Fu. (2022) Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Hejian Guo, Xuehui Yan, Hao Tang & Xiaoyan Zhang. (2022) Assessment of Exenatide loaded Biotinylated Trimethylated Chitosan/HP-
55 Nanoparticles. Current Drug Delivery 19:1, pages 32-40.
Crossref
Crossref
J. Michael Conlon, Finbarr P.M. O’Harte & Peter R. Flatt. (2022) Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy – A review. Peptides 147, pages 170706.
Crossref
Crossref
Kristin Gonzales & Adrian Vella. 2021. Clinical Dilemmas in Diabetes. Clinical Dilemmas in Diabetes
146
160
.
Yuxuan Ge, Zhenhua Hu, Jili Chen, Yujie Qin, Fei Wu & Tuo Jin. (2021) Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide. Pharmaceutics 13:6, pages 816.
Crossref
Crossref
Linong Ji, Ying Du, Min Xu, Xiangjun Zhou, Zhaohui Mo, Jianhua Ma, Jiarui Li, Yufeng Li, Jingna Lin, Yanjun Wang, Jing Yang, Weihong Song, Hui Jin, Shuguang Pang, Hui Liu, Ping Li, Jie Liu, Minxiu Yao, Wenhui Li, Xiaohong Jiang, Feixia Shen, Houfa Geng, Haifeng Zhou, Jianmin Ran, Minxiang Lei, Yinghong Du, Shandong Ye, Qingbo Guan, Wenshan Lv, Huiwen Tan, Tao Chen, Jinkui Yang, Guijun Qin, Shiyun Li & Lei Chen. (2021) Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study. Diabetologia 64:5, pages 1066-1078.
Crossref
Crossref
Giulia Di Dalmazi, Sara Coluzzi, Maria P.A. Baldassarre, Sofia Elena Sorbo, Stefania Dell’Aquila, Fabrizio Febo, Federica Ginestra, Giusi Graziano, Maria C. Rossi, Agostino Consoli & Gloria Formoso. (2020) Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. Clinical Therapeutics 42:9, pages 1738-1749.e1.
Crossref
Crossref
Aimo Kannt, Andreas Nygaard Madsen, Claire Kammermeier, Ralf Elvert, Tim Klöckener, Martin Bossart, Torsten Haack, Andreas Evers, Katrin Lorenz, Wolfgang Hennerici, Corinne Rocher, Zsolt Böcskei, Jean‐Claude Guillemot, Vincent Mikol, Francois Pattou, Bart Staels & Michael Wagner. (2020) Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis. Diabetes, Obesity and Metabolism 22:8, pages 1328-1338.
Crossref
Crossref
Karla de Castro Figueiredo Bordon, Camila Takeno Cologna, Elisa Corrêa Fornari-Baldo, Ernesto Lopes Pinheiro-Júnior, Felipe Augusto Cerni, Fernanda Gobbi Amorim, Fernando Antonio Pino Anjolette, Francielle Almeida Cordeiro, Gisele Adriano Wiezel, Iara Aimê Cardoso, Isabela Gobbo Ferreira, Isadora Sousa de Oliveira, Johara Boldrini-França, Manuela Berto Pucca, Mateus Amaral Baldo & Eliane Candiani Arantes. (2020) From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery. Frontiers in Pharmacology 11.
Crossref
Crossref
Max Sauter, Philipp Uhl, Jürgen Burhenne & Walter E. Haefeli. (2020) Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. Journal of Pharmaceutical Analysis 10:3, pages 233-239.
Crossref
Crossref
Ruth E. Gimeno, Daniel A. Briere & Randy J. Seeley. (2020) Leveraging the Gut to Treat Metabolic Disease. Cell Metabolism 31:4, pages 679-698.
Crossref
Crossref
Yuusuke Watanabe, Yoshifumi Saisho, Jun Inaishi, Kinsei Kou, Akira Yamauchi, Yasuhiko Kanazawa, Yoshiaki Okubo, Mikiya Tokui, Takatoshi Imai, Rie Murakami, Tami Tsuchiya, Hironobu Sasaki, Tatsuhiro Masaoka, Junichiro Irie, Shu Meguro & Hiroshi Itoh. (2019) Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes. Journal of Diabetes Investigation 11:2, pages 382-388.
Crossref
Crossref
Yazhou Li, Kelli L. Vaughan, David Tweedie, Jin Jung, Hee Kyung Kim, Ho-Il Choi, Dong Seok Kim, Julie A. Mattison & Nigel H. Greig. (2019) Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon. Scientific Reports 9:1.
Crossref
Crossref
Henrique de Oliveira Amaral, Victoria Monge-Fuentes, Andréia Biolchi Mayer, Gabriel Avohay Alves Campos, Kamila Soares Lopes, Luana C. Camargo, Matheus Ferroni Schwartz, Priscilla Galante & Márcia R. Mortari. (2019) Animal venoms: therapeutic tools for tackling Parkinson’s disease. Drug Discovery Today 24:11, pages 2202-2211.
Crossref
Crossref
Shigeo Hirasawa, Yoshiro Kitahara, Yoriko Okamatsu, Tomohiro Fujii, Akira Nakayama, Satoko Ueno, Chiori Ijichi, Fumie Futaki, Kunio Nakata & Masumi Taki. (2019) Facile and Efficient Chemoenzymatic Semisynthesis of Fc-Fusion Compounds for Half-Life Extension of Pharmaceutical Components. Bioconjugate Chemistry 30:9, pages 2323-2331.
Crossref
Crossref
Beatriz Elena Sarmiento, Luis Felipe Santos Menezes & Elisabeth F. Schwartz. (2019) Insulin Release Mechanism Modulated by Toxins Isolated from Animal Venoms: From Basic Research to Drug Development Prospects. Molecules 24:10, pages 1846.
Crossref
Crossref
Galyna V. Graham, J. Michael Conlon, Yasser H. Abdel-Wahab & Peter R. Flatt. (2018) Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy. Peptides 110, pages 19-29.
Crossref
Crossref
Liat Soudry-Kochavi, Natalya Naraykin, Rosanna Di Paola, Enrico Gugliandolo, Alessio Peritore, Salvatore Cuzzocrea, Ehud Ziv, Taher Nassar & Simon Benita. (2018) Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles. European Journal of Pharmaceutics and Biopharmaceutics 133, pages 214-223.
Crossref
Crossref
David Stepensky. (2018) Pharmacokinetics of Toxin-Derived Peptide Drugs. Toxins 10:11, pages 483.
Crossref
Crossref
Xu-Dong Wang, Ning-Ning Wei, Shu-Chang Wang, Heng-Li Yuan, Feng-Ying Zhang & Zhi-Long Xiu. (2018) Kinetic Optimization and Scale-Up of Site-Specific Thiol-PEGylation of Loxenatide from Laboratory to Pilot Scale. Industrial & Engineering Chemistry Research 57:44, pages 14915-14925.
Crossref
Crossref
Suleyman Yesil, Nuran Sungu, Aydan Kilicarslan, Serife Kuskonmaz, Halil Kara, Aysegul Kucuk, Fazli Polat, Mustafa Kavutcu & Mustafa Arslan. (2018) Exenatide reduces oxidative stress and cell death in testis in iron overload rat model. Experimental and Therapeutic Medicine.
Crossref
Crossref
Shuchun Chen, Seong-Jin Yu, Yazhou Li, Daniela Lecca, Elliot Glotfelty, Hee Kyung Kim, Ho-Il Choi, Barry J. Hoffer, Nigel H. Greig, Dong Seok Kim & Yun Wang. (2018) Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease. Scientific Reports 8:1.
Crossref
Crossref
Bhawna Kumari, Akanksha Sharma & Umesh C. S. Yadav. 2018. Functional Food and Human Health. Functional Food and Human Health
257
276
.
Guillaume Besch, Andrea Perrotti, Frederic Mauny, Marc Puyraveau, Maude Baltres, Guillaume Flicoteaux, Lucie Salomon du Mont, Benoit Barrucand, Emmanuel Samain, Sidney Chocron & Sebastien Pili-Floury. (2017) Clinical Effectiveness of Intravenous Exenatide Infusion in Perioperative Glycemic Control after Coronary Artery Bypass Graft Surgery. Anesthesiology 127:5, pages 775-787.
Crossref
Crossref
B. Gallwitz. (2017) Rezeptoragonisten des „glucagon-like peptide 1”Receptor agonists of glucagon-like peptide 1. Der Diabetologe 13:7, pages 487-497.
Crossref
Crossref
Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman & Adrian F. Hernandez. (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 377:13, pages 1228-1239.
Crossref
Crossref
Weijie Shang, Xinwang Yang, Xiaoman Ju, Yueying Xie, Yun Zhang & Wen-Hui Lee. (2017)
Characterization of an insulinotropic peptide from skin secretions of
Odorrana andersonii
. Journal of Peptide Science 23:9, pages 707-715.
Crossref
Crossref
Kavisha R. Ulapane, Brian M. Kopec, Mario E. G. Moral & Teruna J. Siahaan. 2017. Peptides and Peptide-based Biomaterials and their Biomedical Applications. Peptides and Peptide-based Biomaterials and their Biomedical Applications
167
184
.
Yong Chen, Shiying Shao, Xiaoling Zhang, Qinqin Xu & Ruping Pan. (2022) Glucagon Like Peptide-1: More than Glucose Control and Weight Reduction. SSRN Electronic Journal.
Crossref
Crossref